Emergent BioSolutions
EBS
$1.98
Share price
-8.94%
Change (1 day)
-80.42%
Change (1 year)
Categories
Operating Margin for Emergent BioSolutions (EBS)
Operating Margin as of April 2024 (TTM): 17.53%
According to Emergent BioSolutions 's latest financial reports and stock price the company's current Operating Margin is 17.53%. At the end of 2021 the company had an Operating Margin of 17.54%.
Operating Margin history for Emergent BioSolutions from 2004 to 2022
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2021 | 17.54% | -33.01% |
| 2020 | 26.18% | 274.09% |
| 2019 | 7.00% | -32.82% |
| 2018 | 10.42% | -50.75% |
| 2017 | 21.15% | 4.2% |
| 2016 | 20.30% | 18.22% |
| 2015 | 17.17% | 45.67% |
| 2014 | 11.79% | -14.99% |
| 2013 | 13.87% | 21.9% |
| 2012 | 11.38% | -2.65% |
| 2011 | 11.68% | -54.42% |
| 2010 | 25.64% | 45% |
| 2009 | 17.68% | -3.57% |
| 2008 | 18.33% | -6.81% |
| 2007 | 19.67% | -20.96% |
| 2006 | 24.89% | 54.1% |
| 2005 | 16.15% | -18.76% |
| 2004 | 19.88% | -80.12% |
| 2003 | 100.00% | 111.56% |
| 2002 | 47.27% | -3965.85% |
| 2001 | -1.22% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin differencediff. | Country |
|---|---|---|---|
 Pfizer PFE | 34.61% | 97.43% | 🇺🇸 USA |
 Merck MRK | 27.73% | 58.19% | 🇺🇸 USA |
 GlaxoSmithKline GSK | 22.54% | 28.58% | 🇬🇧 UK |
 Soligenix SNGX | -1,627.59% | -9,384.60% | 🇺🇸 USA |
 SIGA Technologies SIGA | 66.81% | 281.12% | 🇺🇸 USA |
 Celldex Therapeutics CLDX | -1,520.92% | -8,776.10% | 🇺🇸 USA |
 Teva Pharmaceutical Industries TEVA | -20.53% | -217.11% | 🇮🇱 Israel |
What is a company's Operating Margin
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.